News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
393,698 Results
Type
Article (32322)
Company Profile (59)
Press Release (361317)
Section
Business (114639)
Career Advice (1364)
Deals (24170)
Drug Delivery (88)
Drug Development (59941)
Employer Resources (108)
FDA (9961)
Job Trends (9195)
News (213669)
Policy (25545)
Tag
Academia (1847)
Alliances (42153)
Alzheimer's disease (986)
Approvals (9899)
Artificial intelligence (90)
Bankruptcy (229)
Best Places to Work (7683)
Breast cancer (82)
Cancer (770)
Career advice (1139)
CAR-T (58)
Cell therapy (168)
Clinical research (47212)
Collaboration (294)
Compensation (151)
COVID-19 (2437)
Data (744)
Diabetes (120)
Diagnostics (3431)
Drug pricing (80)
Earnings (39625)
Employer resources (99)
Events (45000)
Executive appointments (134)
FDA (10322)
Funding (214)
Gene therapy (135)
GLP-1 (572)
Government (4035)
Healthcare (11457)
Infectious disease (2517)
Inflammatory bowel disease (64)
Interviews (239)
IPO (10360)
Job creations (1813)
Job search strategy (988)
Layoffs (278)
Legal (7021)
Lung cancer (127)
Manufacturing (131)
Medical device (5871)
Medtech (5872)
Mergers & acquisitions (13871)
Metabolic disorders (350)
Neuroscience (1183)
NextGen Class of 2024 (3730)
Non-profit (2777)
Northern California (900)
Obesity (214)
Opinion (180)
Parkinson's disease (59)
Patents (76)
People (25829)
Phase I (14247)
Phase II (20504)
Phase III (16644)
Pipeline (351)
Policy (65)
Postmarket research (1855)
Preclinical (5913)
Radiopharmaceuticals (201)
Rare diseases (151)
Real estate (2621)
Regulatory (15620)
Research institute (1601)
Resumes & cover letters (209)
Southern California (749)
Startups (1982)
United States (7461)
Vaccines (578)
Weight loss (181)
Date
Last 7 days (614)
Last 30 days (2171)
Last 365 days (22694)
2024 (20501)
2023 (25476)
2022 (33711)
2021 (36285)
2020 (34399)
2019 (28271)
2018 (21536)
2017 (20523)
2016 (18928)
2015 (21726)
2014 (16137)
2013 (12995)
2012 (13786)
2011 (14549)
2010 (13211)
Location
Africa (582)
Arizona (68)
Asia (25704)
Australia (4619)
California (1893)
Canada (766)
China (170)
Colorado (84)
Connecticut (78)
Europe (61786)
Florida (261)
Georgia (63)
Illinois (179)
Indiana (119)
Kansas (56)
Maryland (412)
Massachusetts (1390)
Michigan (72)
Minnesota (84)
New Jersey (602)
New York (618)
North Carolina (345)
Northern California (900)
Ohio (75)
Pennsylvania (466)
South America (810)
Southern California (749)
Texas (226)
Washington State (188)
393,698 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Drug pricing
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.
October 21, 2024
·
2 min read
·
Tristan Manalac
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
Approvals
Novartis Secures First-Line CML Expansion for Scemblix, Projects $3B in Peak Sales
Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic myeloid leukemia. The expanded indication increases the eligible patient population by approximately four times, according to Novartis.
October 30, 2024
·
2 min read
·
Tristan Manalac
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG.
April 30, 2024
·
3 min read
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Business
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
The Management Board and Supervisory Board of MorphoSys AG issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG, recommending that shareholders accept the offer and tender their MorphoSys shares.
April 11, 2024
·
9 min read
Deals
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
MorphoSys AG announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis’ intention to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00 per share in cash.
February 5, 2024
·
16 min read
Press Releases
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
November 12, 2024
·
6 min read
1 of 39,370
Next
